Clinical Trial: Preconceptional Thromboprophylaxis in Recurrent PREGNANCY LOSSES Caused by Antiphospholipid Syndrome
Study Status: Not yet recruiting
Recruit Status: Unknown status
Study Type: Observational
Official Title: A Randomized Clinical Trial of Using Preconceptional Enoxaparin AND Low Dose Aspirin 81mg in Patient With Antiphospholipid Syndrome(APS)
Brief Summary: Preconceptional use of low molecular weight heparin (enoxaparin) and aspirin in patient with recurrent miscarriages with positive anti phospholipid antibodies increase the implantation rate and the duration of pregnancy with low complications to the mother and the baby.
Detailed Summary: Preconceptional heparin during follicular or luteal phase,improves the implantation rate by increasing the blood flow and increasing the implantation factors,also decreasing the pregnancy complication resulting from Antiphospholipid Syndrome (APS).
Sponsor: Woman's Health University Hospital, Egypt
Current Primary Outcome: Pregnancy continuation beyond twelve weeks gestation [ Time Frame: ONE YEAR ]
Original Primary Outcome: Pregnancy continuation beyond twelve weeks gestation [ Time Frame: ONE YEAR ]
Current Secondary Outcome:
Original Secondary Outcome:
Information By: Woman's Health University Hospital, Egypt
Dates:
Date Received: July 25, 2012
Date Started: March 2012
Date Completion: June 2014
Last Updated: June 20, 2014
Last Verified: March 2012